 |
|
Irreversible Disability and Tissue Loss in Multiple Sclerosis
A Conventional and Magnetization Transfer Magnetic Resonance Imaging Study of the Optic Nerves
Matilde Inglese, MD;
Angelo Ghezzi, MD;
Stefania Bianchi, MD;
Simonetta Gerevini, MD;
Maria Pia Sormani, PhD;
Vittorio Martinelli, MD;
Giancarlo Comi, MD;
Massimo Filippi, MD
Arch Neurol. 2002;59:250-255.
ABSTRACT
| |
Objectives To assess, by magnetic resonance imaging, the volumes and magnetization
transfer ratio (MTR) values of optic nerves (ONs) from patients with multiple
sclerosis (MS) who had incomplete or no visual recovery after optic neuritis;
and to compare these quantities with those derived from ONs from patients
with MS who showed a marked clinical recovery after optic neuritis, ONs from
healthy volunteers, and ONs from patients with Leber hereditary optic neuropathy
(LHON).
Methods Conventional and magnetization transfer magnetic resonance images of
the ONs were obtained from 30 patients with MS, 18 healthy volunteers, and
10 patients with LHON. The ON from patients with MS were classified as clinically
unaffected (n = 18); clinically affected with recovery (n = 20; visual acuity  20/25
at least 6 months after optic neuritis); and clinically affected with incomplete
or no recovery (n = 22; visual acuity <20/25 at least 6 months after optic
neuritis). The ON volumes and MTR values were measured.
Results Volumes (P = .002) and MTR values (P<.001) of the ONs from patients with MS and incomplete or no recovery
were both lower than those of the ONs from patients with MS and recovery,
but not different from those of the ONs from patients with LHON. Volumes and
MTR values of the affected ONs from patients with MS and recovery did not
differ from those of clinically unaffected ONs, which were similar to those
of healthy volunteers.
Conclusion These findings suggest that, in patients with MS, neurodegeneration
is associated with persistent functional deficits secondary to incomplete
recovery from relapses.
INTRODUCTION
THE FACTORS leading to irreversible neurologic disability in multiple
sclerosis (MS) are still poorly understood because of the heterogeneity of
the pathologic substrates of the disease and the structural and functional
complexity of the brain and the spinal cord. In this context, the optic nerve
(ON) is of special interest, because it might provide a model for improving
our understanding of how MS causes irreversible disability. There are several
reasons for this. First, the ON is a typical site of MS lesions.1
Second, and different from what happens for other structures of the central
nervous system, the ON subserves a specific function, which can be assessed
reliably by clinical and neurophysiologic methods.2-3
Finally, several recent studies4-10
have shown that magnetic resonance (MR) imaging techniques enable us not only
to obtain high-quality images of the ON, but also to quantify reliably the
extent of ON tissue damage and loss.
Although conventional MR imaging is very sensitive for the detection
of MS lesions, it lacks specificity to the most destructive aspects of the
disease (ie, severe and irreversible demyelination and axonal loss).11 Also, conventional MR imaging is unable to detect
the subtle changes known to occur in the normal-appearing tissue.11 These limitations have been at least partially overcome
by the use of modern MR imaging technology, including magnetization transfer
imaging, and by measuring the volumes of different portions of the central
nervous system.11 Although neither of these
2 approaches provides specific information about demyelination and axonal
loss, they allow estimates to be obtained of overall tissue damage in MS,
which are thought to reflect more closely destructive pathologic changes of
MS within and outside T2-visible lesions than conventional MR imaging does.
Consistent with this, MS-related disability increases with decreasing brain
and cord volumes12-18
and magnetization transfer ratio (MTR) values,19-24
and a postmortem study of patients with MS25
has found a strong correlation between MTR values with the amount of residual
axons in lesions and normal-appearing tissue.
In a previous study,9 our group showed
that patients with Leber hereditary optic neuropathy (LHON), in whom the major
histopathological hallmark of impaired vision is neuronal and axonal loss,26 have dramatically reduced ON volumes and MTR values
when compared with matched healthy volunteers. In the present study, we measured
volumes and MTR of the ONs from a group of patients with MS and a single previous
episode of optic neuritis and compared them with those of patients with LHON
and matched healthy volunteers. To improve our understanding of the factors
underlying irreversible deficits in MS, we divided affected ONs from patients
with MS into 2 groups according to the degree of subsequent clinical recovery,
and reasoned that if axonal loss is the major factor associated with "fixed"
MS deficits, ONs with incomplete clinical recovery should have had volumes
and MTR values similar to those of ONs from patients with LHON, whereas previously
affected ONs with subsequent satisfactory clinical recovery should have had
volumes and MTR values similar to those of ONs from healthy volunteers. Since
demyelination might also contribute to reduced ON volumes and MTR values,25 in patients with MS we also obtained visual evoked
potentials (VEPs). Persistent delay of the P100 wave of the pattern-reversal
VEP after an episode of optic neuritis is considered to be compatible with
residual demyelination within the ON.2-3
Thus, we postulated that if irreversible demyelination is not a critical factor
contributing to fixed deficits in MS, the P100 latency of ONs from patients
with MS should be independent of the degree of clinical recovery.
PATIENTS AND METHODS
SUBJECTS
We studied 30 patients with relapsing-remitting and secondary progressive
MS.27 All patients had to have a single previous
episode of acute optic neuritis confirmed by a complete and standardized neuro-ophthalmologic
assessment (including color vision and visual field testing) and to have been
clinically stable for at least 6 months. In addition, they had had neither
relapses nor corticosteroid treatment during the preceding 3 months. Optic
nerves from patients with MS were classified as follows: (1) clinically affected
with incomplete or no recovery when best-corrected visual acuity (VA), assessed
with wall charts, was less than 20/25 at least 6 months after the attack;
(2) clinically affected with recovery when best-corrected VA was equal to
or greater than 20/25 at least 6 months after the attack; and (3) clinically
unaffected. Two control groups were identified. The first consisted of 18
sex- and age-matched healthy volunteers, with no history of neurologic diseases
and with normal results of neurologic and ophthalmologic examinations. The
second control group consisted of 10 age-matched patients with LHON documented
by 1 of the 3 primary mitochondrial DNA mutations (7 patients had the 11778,
2 the 3460, and 1 the 14484 mutation). A complete ophthalmologic evaluation
was performed by one physician (S.B.), who was unaware of the MR imaging results,
in all subjects. In patients with MS, disability was measured with the Expanded
Disability Status Scale.28 Additional demographic
and clinical characteristics of the subjects studied are reported in Table 1. Local ethical committee approval
and written informed consent from all the subjects were obtained before study
initiation.
|
|
|
|
Table 1. Demographic and Clinical Characteristics of Healthy Volunteers
and Patients With MS and LHON*
|
|
|
MR IMAGE ACQUISITION AND PROCESSING
The ONs of all subjects were imaged in a single session, by means of
a standard head coil and a scanner operating at 1.5 T. The following sequences
were obtained: (1) T2-weighted turbo spin echo (repetition time [TR], 4230
milliseconds; echo time [TE], 119 milliseconds; echo train length, 15; 15
coronal slices with 3-mm thickness; interslice gap, 0.3 mm; matrix size, 180
x 512; and field of view [FOV], 156 x 250 mm); (2) T1-weighted
spin echo (TR, 500 milliseconds; TE, 14 milliseconds; 15 coronal slices with
3-mm thickness; interslice gap, 0.3 mm; matrix size, 224 x 512; and
FOV, 156 x 250 mm); and (3) 2-dimensional gradient echo (TR, 640 milliseconds;
TE, 12 milliseconds; flip angle, 20°; 15 contiguous coronal slices with
5-mm thickness; matrix size, 256 x 256; and FOV, 250 x 250 mm),
with and without an off-resonance radiofrequency saturation pulse (offset
frequency, 1.5 kHz; gaussian envelope duration, 7.68 milliseconds; flip angle,
500°). During ON imaging, all subjects were asked to close their eyes
and possibly avoid eye movements. We also obtained dual-echo turbo spin-echo
(TR, 3300 milliseconds; TE, 16-98 milliseconds; echo train length, 5; 24 contiguous
axial slices with 5-mm thickness; matrix size, 192 x 256; and FOV, 188
x 250 mm) images of the brain from all subjects.
The volumes of the ON were measured on T1-weighted images. A single
observer (M.I.), unaware of subjects' identity, calculated the areas of the
ON sections from 11 consecutive 3-mm-thick slices, starting from the first
slice showing the chiasm and moving backward (ie, toward the eye) and using
a local thresholding techniquefor tissue segmentation.29
The ON volumes were then calculated by multiplying the sum of these areas
for the slice thickness. From the corresponding 2 gradient echo images and
after image coregistration with the use of an algorithm based on mutual information,30 we derived quantitative MTR maps of the ON, as extensively
described elsewhere.21 After ON and chiasm
segmentation from the MTR maps, the average MTR value was calculated for the
same tract considered for ON volume measurements. Because of the different
slice thickness, 7 consecutive 5-mm-thick MTR slices, starting from the first
slice showing the chiasm and going backward, were used. The MTR value for
each slice was derived from a small region of interest (4 pixels) placed in
the center of the ON section. The pixels adjacent to the nerve borders were
excluded from the analysis, to minimize the influence of partial volume effects
from the cerebrospinal fluid. An ON was considered to be atrophic or to have
abnormal MTR values when its volume or MTR values were at least 2 SDs below
the mean values obtained for the ONs from the healthy volunteers. Dual-echo
images of the brain were reviewed by 2 observers (M.I. and S.G.), unaware
of subjects' identity, to identify hyperintense lesions.
VISUAL EVOKED POTENTIALS
A black-and-white checkerboard pattern on a square television screen,
reversing every 0.7 milliseconds, was used to obtain pattern-reversal VEPs.
The entire stimulating field was 11°; 30' check size was used. The contrast
was kept constant at 70%. The cortical responses were recorded from Oz referred
to Cz. The bandwidth was 1 to 250 Hz. An average of 100 responses were used
to obtain the VEP. The P100 latency was considered abnormal if it was more
than 2.5 SDs above the mean of the healthy volunteers.
STATISTICAL ANALYSIS
Volumes and MTR values among the 5 groups of ONs (MS affected, with
no or incomplete recovery; MS affected, with recovery; MS unaffected; normal;
and LHON) were compared by means of a random effect model (random intercept),
which allows correlations existing for any of the variables tested between
the 2 ONs from the same individual to be accounted for. Four contrasts were
decided a priori on the basis of the available degrees of freedom and biological
considerations. The following were the a priori contrasts we tested: (1) normal
ON vs MS clinically unaffected ON; (2) MS clinically unaffected ON vs MS affected
ON with recovery; (3) MS affected ON with recovery vs MS affected ON with
incomplete or no recovery; and (4) MS affected ON with incomplete or no recovery
vs LHON ON. Univariate correlations were assessed with the Spearman rank correlation
coefficient, with P values corrected to account for
the correlations existing between the 2 ONs from the same individual. A multivariable
linear regression model was used to generate a composite MR score to be correlated
with the VA in patients with MS. This was computed by means of a linear combination
of ON volumes (reflecting the extent of tissue loss) and MTR values (reflecting
the intrinsic abnormality of the residual tissue). The weight of each MR parameter
resulted from the coefficients estimated by the regression model. The magnitude
and the significance of the correlation was evaluated by a nonparametric Spearman
correlation analysis. Pairwise comparisons were performed with a Student t test for unpaired data, again correcting for the correlation
existing between the 2 ONs of the same individual.
RESULTS
In the MS population, there were 18 clinically unaffected ONs, 20 affected
ONs with recovery (VA was 20/25 in 5 patients and 20/20 in 15 patients), and
22 affected ONs with incomplete or no recovery (VA was light perception in
1 case, counting fingers in 2, 20/100 in 5, 20/80 in 2, 20/70 in 1, 20/40
in 2, and 20/30 in 9). In patients with LHON, VA was 20/400 bilaterally in
3 patients, counting fingers OD and 20/100 OS in 2 patients, light perception
OD and hand movements OS in 1 patient, counting fingers bilaterally in 2 patients,
and hand motions bilaterally in 1 patient.
No brain or ON lesions were detected on any of the MR images obtained
from healthy volunteers and patients with LHON. All patients with MS had abnormal
brain MR images and met the criteria of Fazekas et al.31
The MR images of 2 ONs from patients with MS (1 with no or incomplete recovery
and 1 with recovery) were of suboptimal quality, and, as a consequence, they
were not considered in the following analyses. Five MS ONs with incomplete
or no recovery (24%) and 3 of those with recovery (16%) had a hyperintense
lesion on the dual-echo images. The lengths of these lesions ranged from 3
to 9 mm. Seven of them were located in the intracanalicular portion, while
1 was located in the intraorbital portion of the ON.
Table 2 gives the mean volumes
and MTR values from the ONs of all the subjects. Volumes and MTR values of
the affected MS ONs with incomplete or no recovery were both significantly
lower (P = .002 and P<.001,
respectively) than the corresponding quantities of the MS ONs with recovery,
whereas both of these quantities did not differ from those of the ONs from
patients with LHON. Also, volumes and MTR values of the affected MS ONs with
recovery did not differ from the corresponding quantities of clinically unaffected
ONs, which in turn had volumes and MTR values similar to those of the ONs
from healthy volunteers. The same results were obtained when a VA cutoff of
20/50 was used for incomplete recovery (data not shown).
|
|
|
|
Table 2. Mean ON Volumes and MTR Values From Healthy Volunteers and
Patients With MS and LHON*
|
|
|
Visual evoked potentials were obtained from 25 patients with MS (14
clinically unaffected ONs, 18 affected ONs with recovery, and 18 affected
ONs with incomplete or no recovery). The VEPs could not be obtained from 9
ONs with incomplete or no recovery. The mean P100 latencies were 99.6 milliseconds
(SD, 4.5 milliseconds) for healthy control subjects, 114.1 milliseconds (SD,
19.6 milliseconds) for clinically unaffected ONs (P
= .008 vs control subjects), 126.7 milliseconds (SD, 22.6 milliseconds) for
affected ONs with recovery (P<.001 vs control
subjects), and 154.5 milliseconds (SD, 20.3 milliseconds) for affected ONs
with incomplete or no recovery whose P100 could be elicited (P<.001 vs control subjects). In Table 3, the numbers and percentages of ON with atrophy, abnormal
MTR values, and abnormal P100 latency are reported for each of the categories
studied. The percentage of ONs with atrophy and abnormal MTR values were similar
in MS ONs with incomplete or no recovery and ONs from patients with LHON.
|
|
|
|
Table 3. Optic Nerves With Atrophy, Abnormal MTR Values, and Abnormal
P100 Latency*
|
|
|
In patients with MS, ON volumes and MTR were moderately correlated (r = 0.46, P = .001). The VA was
correlated with ON volume (r = 0.39, P = .01), MTR values (r = 0.49, P = .001), and P100 latency (r = -0.57, P<.001). No statistically significant correlation was
found between P100 latency and MTR values (r = -0.10),
whereas P100 latency and ON volumes were moderately correlated (r = -0.31, P = .05). A moderate correlation
was also found between the VA and the MR composite score (r = 0.53, P<.001).
COMMENT
There is increasing appreciation that neurodegeneration is the major
factor underlying the accumulation of disability in MS and that inflammatory
demyelination alone is not sufficient to explain the neurologic dysfunction
in this disease.32 Although neurodegeneration
has been known to occur in MS from the early descriptions of Charcot, the
major pieces of evidence suggesting the importance of this aspect of the disease
for disability in MS come from MR spectroscopy studies,32
showing that the level of brain N-acetyl-aspartate,
a marker of axonal integrity,33 is strictly
correlated with the degree of disability in patients with MS.34-36
Accumulation of disability in MS can be secondary to a progressive disease
course or to incomplete recovery after acute relapses.27
Previous studies have been mainly focused on understanding the progressive
accumulation of disability,32 whereas the factors
related to incomplete recovery after an acute injury are still to be elucidated.
This lack of knowledge is secondary to the fact that, because of the anatomic
and functional complexity of the brain and the spinal cord and the multifocality
of the disease, it is virtually impossible to define the exact role of regional
tissue damage in determining fixed neurologic deficits in MS. In this respect,
the assessment of MS-related tissue damage in the ON can be viewed as an excellent
model to investigate the effect of the various components of MS abnormality
on the clinical manifestations of the disease. Until recently, however, MR
imaging of the ON was limited by its small size, motion artifacts, and the
effect of surrounding cerebrospinal fluid, lipid, and bony structures.37 Although MR imaging of the ON remains technically
challenging, several studies have shown that with careful optimization, it
is possible to obtain high-quality T1- and T2-weighted images, as well as
reliable quantitative measurements of MR quantities, including the MTR.4-10
Against this background, the present study was performed to increase
our understanding of the factors associated with irreversible disability after
MS relapses. This study has demonstrated a reduction in the volume and MTR
values of the ON from patients with MS, which, after an episode of optic neuritis,
showed no or only an incomplete functional recovery. The volume and MTR reductions
found in these ONs were not different from those found in patients with LHON,
a condition in which there is loss of neurons and axons.26
In contrast, affected ONs that recovered after the disease injury had volumes
and MTR values higher than those of ONs with incomplete or no recovery and
similar to those of clinically unaffected ONs and of ONs from healthy volunteers.
We also showed a graded relationship between these 2 MR quantities and VA
in patients with MS. Although neither ON volume reductions nor MTR decreases
are specific markers of axonal loss, we interpret these findings as an indication
that loss of axonal integrity is associated with persistent functional deficit
in MS due to incomplete recovery from relapses.
Several previous studies have shown that brain and spinal cord atrophy
occurs in MS and correlates with the degree of disability.12-18
Although the pathologic basis of atrophy in MS is not fully elucidated, axonal
loss is likely to be an important contributing factor, since axons represent
the largest proportion of the white matter volume,38
and there is evidence of considerable axonal damage in MS lesions and normal-appearing
tissue.39-41 All
of this is in keeping with the findings of this study showing that a similar
average degree of ON volume and a similar frequency of ON atrophy are detectable
in the ON with incomplete or no recovery from patients with MS and in those
from patients with LHON.
The same considerations apply to the interpretation of the MTR changes
seen in this study. Low MTR values correspond to areas where the relative
proportion of water bound to macromolecules is reduced, indicating a loss
of microstructural tissue integrity. Consistent with this, several studies
have shown that brain and cervical cord MTR changes are correlated with disability
in patients with MS.19-24
Axonal loss is likely to be an important contributor to MTR decreases in MS
for several reasons. First, a postmortem study of patients with MS has shown
that a strict correlation exists between MTR values and percentage amounts
of residual axons.25 Second, MTR reduction
has been found to correlate well with N-acetyl-aspartate–creatine
ratio measured in MS lesions.42 Third, low
MTR values have been found in animal models of wallerian degeneration43 and diffuse axonal injury.44
Given that ON volume and MTR reductions can also be related to persistent
demyelination, we obtained VEPs from patients with MS. Because an increased
P100 latency weeks or months after an acute episode of optic neuritis is considered
to be a marker of residual demyelination,2-3
we focused our analysis on this component of the VEP. Although the ONs with
incomplete or no recovery were those in which the P100 was more frequently
abnormal, we also found that a large proportion of clinically unaffected ONs
(64%) and affected ONs with subsequent recovery (89%) had increased P100 latencies.
The mean P100 latencies of clinically unaffected ONs and affected ONs with
subsequent recovery were also significantly increased compared with those
from healthy subjects. These findings, which agree with those of previous
studies,2, 5 support the concept
that demyelination per se is not sufficient to explain fixed neurologic symptoms
after acute damage.
In this study, we also showed significant correlations between VA and
ON volumes and MTR values. The composite MR score, based on a measure reflecting
the amount of tissue loss (ON volume) and on a measure reflecting the integrity
of the residual tissue (ON MTR), was also correlated with the VA. The magnitude
of these correlations was, however, moderate and perhaps lower than expected.
There are several reasons that might explain this finding. First, VA is not
only related to the amount of tissue damage occurring in the ON, but also
to that occurring along the entire visual pathways. Given the high interpatient
variability in MS lesion location, the amount of abnormality occurring beyond
the ON might well be a factor reducing the strength of the correlation. Second,
functional MR imaging studies have shown a marked intersubject variability
of cortical adaptive reorganization after MS injury,45-46
including optic neuritis.47-48
Again, this might yet be an additional confounding factor. Third, atrophy
and abnormal MTR values are found in 20% to 30% of clinically unaffected ONs
and in about 20% to 40% of the affected ONs with subsequent satisfactory clinical
recovery. This indicates that the system is redundant enough to limit, at
least to a certain extent, the consequences of tissue loss and damage. Finally,
as mentioned earlier, ON volumes and MTR values do not simply reflect tissue
loss and damage, and, as a consequence, other factors might lead to underestimation
(eg, reactive gliosis in the case of ON volume measurements) or overestimation
(eg, demyelination in the case of MTR measurements) of the extent of "disabling"
disease, thus reducing the magnitude of the correlation with the clinical
outcome.
AUTHOR INFORMATION
Accepted for publication September 24, 2001.
Author contributions: Study concept and design (Drs Inglese, Bianchi, Comi, and Filippi); acquisition
of data (Drs Inglese, Ghezzi, Bianchi, Gerevini, and Martinelli); analysis and interpretation of data (Drs Inglese,
Gerevini, Sormani, and Filippi); drafting of the manuscript (Drs Inglese and Filippi); critical revision of the manuscript for
important intellectual content (Drs Inglese, Ghezzi, Bianchi,
Gerevini, Sormani, Martinelli, Comi, and Filippi); statistical expertise (Dr Sormani); administrative, technical, or material support (Drs Inglese, Ghezzi, Bianchi, Gerevini, Martinelli, and Comi); supervision (Dr Filippi).
Corresponding author and reprints: Massimo Filippi, MD, Neuroimaging
Research Unit, Department of Neuroscience, Scientific Institute and University
Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy (e-mail: filippi.massimo{at}hsr.it).
From the Neuroimaging Research Unit (Drs Inglese, Sormani, and Filippi)
and Clinical Trials Unit (Drs Martinelli and Comi), Department of Neuroscience,
and Departments of Ophthalmology (Dr Bianchi) and Neuroradiology (Dr Gerevini),
Scientific Institute and University Ospedale San Raffaele, Milan, Italy; and
Multiple Sclerosis Centre, Ospedale di Gallarate, Gallarate, Italy (Dr Ghezzi).
REFERENCES
| |
1. Matthews B. Symptoms and signs of multiple sclerosis In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle
H, eds. McAlpine's Multiple Sclerosis. 3rd ed. London, England:
Churchill Livingstone; 1998:145-190.
2. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis: an association of gadolinium
leakage with clinical and electrophysiological deficits. Brain. 1991;114:2437-2450.
FREE FULL TEXT
3. McDonald WI, Barnes D. The ocular manifestations of multiple sclerosis, 1: abnormalities of
the afferent visual system. J Neurol Neurosurg Psychiatry. 1992;55:747-752.
ISI
| PUBMED
4. Gass A, Barker GJ, MacManus D, et al. High resolution magnetic resonance imaging of the anterior visual pathway
in patients with optic neuropathies using fast spin echo and phased array
local coils. J Neurol Neurosurg Psychiatry. 1995;58:562-569.
ABSTRACT
5. Thorpe JW, Barker GJ, Jones SJ, et al. Magnetisation transfer ratios and transverse magnetisation decay curves
in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry. 1995;59:487-492.
ABSTRACT
6. Gass A, Moseley IF, Barker GJ, et al. Lesion discrimination in optic neuritis using high-resolution fat-suppressed
fast spin-echo MRI. Neuroradiology. 1996;38:317-321.
ISI
| PUBMED
7. Boorstein JM, Moonis G, Boorstein SM, Patel YP, Culler AS. Optic neuritis: imaging with magnetization transfer. AJR Am J Roentgenol. 1997;169:1709-1712.
FREE FULL TEXT
8. Iwasawa T, Matoba H, Ogi A, et al. Diffusion-weighted imaging of the human optic nerve: a new approach
to evaluate optic neuritis in multiple sclerosis. Magn Reson Med. 1997;38:484-491.
ISI
| PUBMED
9. Inglese M, Rovaris M, Bianchi S, et al. Magnetic resonance imaging, magnetisation transfer imaging and diffusion
weighted imaging correlates of optic nerve, brain and cervical cord damage
in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry. 2001;70:444-449.
FREE FULL TEXT
10. Hickman SJ, Brex PA, Brierley CMH, et al. Detection of optic nerve atrophy following a single episode of unilateral
optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence. Neuroradiology. 2001;43:123-128.
FULL TEXT
|
ISI
| PUBMED
11. Filippi M. Linking structural, metabolic and functional changes in multiple sclerosis. Eur J Neurol. 2001;8:291-297.
FULL TEXT
|
ISI
| PUBMED
12. Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple
sclerosis. J Neurol. 1996;243:502-505.
FULL TEXT
|
ISI
| PUBMED
13. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain. 1996;119:2009-2019.
FREE FULL TEXT
14. Losseff NA, Webb SL, O'Riordan J, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible
and sensitive MRI method with potential to monitor disease progression. Brain. 1996;119:701-708.
FREE FULL TEXT
15. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998;51:234-238.
FREE FULL TEXT
16. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy
in relapsing-remitting MS. Neurology. 1999;53:1698-1704.
FREE FULL TEXT
17. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt L. Three dimensional MRI estimates of brain and spinal cord atrophy in
multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;66:323-330.
FREE FULL TEXT
18. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary
progressive multiple sclerosis: longitudinal quantitative analysis. Radiology. 2000;214:665-670.
FREE FULL TEXT
19. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with disability in multiple
sclerosis. Ann Neurol. 1994;36:62-67.
FULL TEXT
|
ISI
| PUBMED
20. van Buchem MA, Grossman RI, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical
data in MS. Neurology. 1998;50:1609-1617.
ABSTRACT
21. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization
transfer MRI. Neurology. 1999;52:588-594.
FREE FULL TEXT
22. Iannucci G, Minicucci L, Rodegher M, Sormani MP, Comi G, Filippi M. Correlations between clinical and MRI involvement in multiple sclerosis:
assessment using T1, T2 and MT histograms. J Neurol Sci. 1999;171:121-129.
FULL TEXT
|
ISI
| PUBMED
23. Filippi M, Bozzali M, Horsfield MA, et al. A conventional and magnetization transfer MRI study of the cervical
cord in patients with multiple sclerosis. Neurology. 2000;54:207-213.
FREE FULL TEXT
24. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal appearing brain
tissue in multiple sclerosis. Neurology. 2000;54:186-193.
FREE FULL TEXT
25. vanWaesberghe JH, Kamphorst W, de Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging
insights into substrates of disability. Ann Neurol. 1999;46:747-754.
FULL TEXT
|
ISI
| PUBMED
26. Saadati HG, Husu HY, Heller KB, Sadun AA. A histopathologic and morphometric differentiation of nerves in optic
nerve hypoplasia and Leber hereditary optic neuropathy. Arch Ophthalmol. 1998;116:911-916.
FREE FULL TEXT
27. Lublin FD, Reingold SC for the National Multiple Sclerosis Society (USA) Advisory Committee
on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international
survey. Neurology. 1996;46:907-911.
FREE FULL TEXT
28. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability
status scale (EDSS). Neurology. 1983;33:1444-1452.
FREE FULL TEXT
29. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new putative markers of
demyelination and axonal loss in multiple sclerosis: a comparison with conventional
T2-weighted images. J Neurol. 1997;244:266-270.
FULL TEXT
|
ISI
| PUBMED
30. Studholme C, Hill DLG, Hawkes DJ. Automated 3D registration of MR and PET brain images by multi-resolution
optimisation of voxel similarity measures. Med Phys. 1997;24:25-35.
FULL TEXT
|
ISI
| PUBMED
31. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly
subjects with suspected multiple sclerosis. Neurology. 1988;38:1822-1825.
FREE FULL TEXT
32. Arnold DL, De Stefano N, Narayanan S, Matthews PM. Axonal injury and disability in multiple sclerosis: magnetic resonance
spectroscopy as a measure of dynamic pathological change in white matter. In: Filippi M, Arnold DL, Comi GC, eds. Magnetic
Resonance Spectroscopy in Multiple Sclerosis. Milan, Italy: Springer;
2001:61-67.
33. Simmons ML, Frondoza CG, Coyle JT. Immunohistochemical localization of N-acetyl-aspartate
with monoclonal antibodies. Neuroscience. 1991;45:37-45.
FULL TEXT
|
ISI
| PUBMED
34. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative
MRI morphometry and magnetic resonance spectroscopy. Brain. 1996;119:715-722.
FREE FULL TEXT
35. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting
multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy
study. Brain. 1998;121:1469-1477.
FREE FULL TEXT
36. Fu L, Matthews PM, De Stefano N, et al. Imaging of axonal damage of normal appearing white matter in multiple
sclerosis. Brain. 1998;121:103-113.
FREE FULL TEXT
37. Barker GJ. Diffusion-weighted imaging of the spinal cord and optic nerve. J Neurol Sci. 2001;186(suppl 1):S45-S49.
38. Adams C. Colour Atlas of Multiple Sclerosis and Other Demyelinating
Disorders. Ipswich, England: Wolfe Medical Publications Ltd; 1989.
39. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically
normal white matter in multiple sclerosis. J Neurol Sci. 1979;41:81-91.
FULL TEXT
|
ISI
| PUBMED
40. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L. Axon transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
FREE FULL TEXT
41. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral
white matter lesion volume and distribution in multiple sclerosis. Brain. 2000;123:1845-1849.
FREE FULL TEXT
42. Hiehle JF Jr, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the
evaluation of demyelinating lesions and normal appearing white matter in multiple
sclerosis. Magn Reson Med. 1994;32:285-293.
ISI
| PUBMED
43. Lexa FJ, Grossman RI, Rosenquist AC. MR of wallerian degeneration in the feline visual system: characterization
by magnetization transfer rate with histopathologic correlation. AJNR Am J Neuroradiol. 1994;15:201-212.
ABSTRACT
44. Kimura H, Meaney DF, McGowan JC, et al. Magnetization transfer imaging of diffuse axonal injury following experimental
brain injury in the pig: characterization by magnetization transfer ratio
with histopathologic correlation. J Comput Assist Tomogr. 1996;20:540-546.
FULL TEXT
|
ISI
| PUBMED
45. Lee M, Reddy H, Johansen-Berg H, et al. The motor cortex shows adaptative functional changes to brain injury
from multiple sclerosis. Ann Neurol. 2000;47:606-613.
FULL TEXT
|
ISI
| PUBMED
|
